Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.WT

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Claridgeon Jun 26, 2019 4:45pm

63 Views

Post# 29866988

RE:RE:RE:RE:RE:RE:RE:RE:Rutherrin

Eoganacht ... Accurate.

______________________

Eoganacht - (6/26/2019 4:02:09 PM)
RE:RE:RE:RE:RE:RE:RE:Rutherrin

The link to the online journal was provided by Enrique earlier today:

Neuro-Oncology Advances

ACCEPTED MANUSCRIPT

Efficacy of Ruthenium coordination complex based Rutherrin in a pre-clinical rat glioblastoma(GBM) model

Manjunatha Akathatti Munegowda Carl Fisher Daniel Molehuis Warren Foltz Mark Roufaiel Jay Bassan Mark Nitz Arkady Mandel Lothar Lilge

Published: 28 May 2019

If you click on the PDF link and go to the last paragraph of page 20 you will see:

"Rutherrin-PDT was well tolerated, providing safe and effective treatment of RG-2 glioma. Rutherrin mediated PDT response appears superior to ALA-PpIX mediated PDT. In our

unpublished clinical study, photosensitizer present in Rutherrin formulation has not shown any phototoxicity, excluding patients from avoiding light sources. With these positive PDT results

and the ability to absorb light at longer wavelengths, resistance photobleaching, Rutherrin is a promising photosensitizer formulation to target brain cancer."

hydrocarbss wrote:fredgoodwinson wrote

'In our unpublished clinical study, photosensitizer present in Rutherrin formulation has not shown any phototoxicity, excluding patients from avoiding light sources.'

I questioned the source.

B$ reply:

billiondolarman - (6/26/2019 3:24:17 PM)
RE:RE:RE:RE:RE:Rutherrin
Todays news release. If you take the time to read it.>>>BDM

My response: That statement, re: an unpublished clinical study...

cannot be found in the news release of June 26, 2019 from Theralase.